#nivolumab/ipilimumab
LightNews LightNews
jama.com
The incidence and prevalence of #melanoma, the fifth most common cancer in the US, have increased over the last 5 decades.

This Review summarizes the epidemiology, pathophysiology, diagnosis, and treatment of cutaneous melanoma.

ja.ma/4j1AhEC
Diagram of melanoma cell immunotherapy, detailing mechanisms of action of drugs like Ipilimumab, Nivolumab, and Vemurafenib. Highlights interactions between immune cells (T cells) and melanoma cells, targeting pathways like CTLA-4, PD-1, and MAPK signaling.
December 16, 2025 at 4:45 PM
drugs.com
Melanoma breakthrough: Lower immunotherapy doses = better results! New study shows "flipped dose" treatment with #nivolumab/ipilimumab improved survival (42 vs 14 months) with fewer side effects. Sometimes, less is more in cancer treatment. www.drugs.com/news/less-mo...
Less Is More For Melanoma-Fighting Immunotherapy, Nivolumab/Ipilimumab, Study Argues - Drugs.com MedNews
FRIDAY, Dec. 12, 2025 Less might be more when it comes to immunotherapy treatment of melanoma, a new study says. Lower doses of a drug used to treat melanoma ca
www.drugs.com
December 12, 2025 at 6:13 PM
vcclibrary.bsky.social
The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study. @velindrecc.bsky.social www.ejcancer.com/article/S095...
The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study
Immune checkpoint inhibitor (ICI) combinations have improved outcomes in patients with advanced melanoma; however, long term survival remains poor. The addition of therapeutic cancer vaccines to ICI c...
www.ejcancer.com
December 11, 2025 at 2:10 PM
infarmacocosisifa.bsky.social
L’immunoterapia ha migliorato la sopravvivenza nel melanoma avanzato. Uno studio su 1.000 pazienti mostra che la combinazione nivolumab + ipilimumab offre risultati migliori rispetto ai singoli farmaci.
Leggi l’articolo completo sul portale InFarmaco
infarmaco.it/melanoma-le-...
#cosisifa
December 11, 2025 at 11:03 AM
vcclibrary.bsky.social
The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): a randomized open-label phase 2 study. www.ejcancer.com/article/S095...
The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): a randomized open-label phase 2 study
Immune checkpoint inhibitor (ICI) combinations have improved outcomes in patients with advanced melanoma; however, long term survival remains poor. The addition of therapeutic cancer vaccines to ICI c...
www.ejcancer.com
December 4, 2025 at 11:59 AM
oncodaily.bsky.social
Real-World Outcomes of First-Line Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma: Insights From the GUARDIANS Multicenter Cohort

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Ipilimumab #Nivolumab #RenalCellCarcinoma #RCC
Real-World Outcomes of First-Line Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma: Insights From the GUARDIANS Multicenter Cohort - OncoDaily
Real-world data show ipilimumab + nivolumab provides meaningful survival benefits in advanced Renal Cell Carcinoma, with outcomes shaped by risk, histology, and toxicity.
oncodaily.com
December 1, 2025 at 6:59 PM
natmed.nature.com
In a phase 1 trial, treatment of fibrolamellar hepatocellular carcinoma with a therapeutic peptide vaccine targeting the DNAJB1::PRKACA fusion, together with nivolumab and ipilimumab, was safe and led to encouraging preliminary clinical responses. https://www.nature.com/articles/s41591-025-03995-y
December 1, 2025 at 1:00 PM
natmed.nature.com
In a phase 1 trial, treatment of fibrolamellar hepatocellular carcinoma with a therapeutic peptide vaccine targeting the DNAJB1::PRKACA fusion, together with nivolumab and ipilimumab, was safe and led to encouraging preliminary clinical responses. https://www.nature.com/articles/s41591-025-03995-y
November 26, 2025 at 1:01 PM
weldeiry.bsky.social
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence

www.nature.com/articles/s41...
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence - Nature Communications
Therapeutic options for patients with renal medullary carcinoma (RMC) are limited. Here the authors report the results of a phase II clinical trial of anti-PD1 nivolumab plus anti-CTLA4 ipilimumab in ...
www.nature.com
November 26, 2025 at 1:32 AM
bigearthdata.bsky.social
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence
->Nature | More from Lil Dr Glen EcoChat at BigEarthData.ai
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence
The trial was designed and conducted at the University of Texas MD Anderson Cancer Center (MDACC), registered under clinicaltrials.gov identifier NCT03274258, approved by the MDACC institutional review board (IRB)/independent ethics committee (IRB protocol 2017-0201) and conducted in accordance with Good...
www.nature.com
November 25, 2025 at 9:29 PM
updates.chemo.org.uk
Nivolumab and ipilimumab- Nivolumab in combination with ipilimumab for treating advanced melanoma

https://updates.chemo.org.uk/CDF_Forms/NIV18.html

🚨 Treatment criterion (#4) updated
November 18, 2025 at 9:04 AM
updates.chemo.org.uk
Nivolumab- Nivolumab monotherapy (with or without initial combination treatment with ipilimumab) for treating unresectable advanced malign...

https://updates.chemo.org.uk/CDF_Forms/NIV8a.html

🚨 Treatment criterion (#4) updated
November 18, 2025 at 9:04 AM
sciencex.bsky.social
A multicenter clinical trial reports that combining nivolumab and ipilimumab leads to higher response rates and prolonged disease control in advanced dMMR/MSI-H rare cancers. doi.org/hbbfcc
Combination immunotherapy for rare cancers shows improved efficacy and survival rates
New results from a multicenter clinical trial show that combining immunotherapy drugs nivolumab and ipilimumab significantly improves treatment response in patients with advanced and difficult-to-treat cancers.
medicalxpress.com
November 14, 2025 at 3:32 PM
jamaoncology.com
In a nonrandomized phase 2 trial of adults with advanced dMMR/MSI-H noncolorectal cancers, combined nivolumab/ipilimumab showed an objective response rate of 63% and 6-month progression-free survival rate of 71%. ja.ma/49mKIQp
Waterfall plot titled 'Figure 1. Efficacy Outcomes: Tumor change of target lesions'. Y-axis shows 'Change from baseline, %,' ranging from 20% to -100%. Bars indicate tumor type, Endometrium (orange) and Other (green). Legend includes response, MSI, and MMR IHC statuses.
November 13, 2025 at 4:30 PM
dimduning.bsky.social
(för icke onk-nördar blir det typ: ”vid fjärrspridd tjock-eller ändtarmscancer som är genetiskt instabil enligt ett särskilt mönster, ger kombinationen av immunterapiantikropparna ipilimumab och nivolumab förlängd tid innan man kan se på röntgen att tumörerna har växt, jämfört med bara nivolumab.”
November 7, 2025 at 7:50 AM
alliance-org.bsky.social
Glenn J. Hanna, MD, of the Dana-Farber Cancer Institute leads Alliance A092105 trial testing the immunotherapy drugs nivolumab and ipilimumab when used with or without the drug cabozantinib when treating patients with advanced nasopharyngeal cancer. Learn more at https://bit.ly/Alliance-A092105.

October 31, 2025 at 2:01 PM
natrevgastrohep.nature.com
NOVEMBER ISSUE | RESEARCH HIGHLIGHT "Aspirin and recurrence of PI3K-mutated CRC"

www.nature.com/articles/s41...

#Gastrosky #Oncsky
Research Highlights: NeuroGASTRO 2025 Maternal gut microbiome in early pregnancy: predictor of preterm birth? Nivolumab and ipilimumab as neoadjuvant therapy for potentially resectable HCC Aspirin and recurrence of PI3K-mutated CRC
October 27, 2025 at 3:42 PM
natrevgastrohep.nature.com
NOVEMBER ISSUE | RESEARCH HIGHLIGHT "Nivolumab and ipilimumab as neoadjuvant therapy for potentially resectable HCC"

www.nature.com/articles/s41...

#Liversky #Oncsky
Research Highlights: NeuroGASTRO 2025 Maternal gut microbiome in early pregnancy: predictor of preterm birth? Nivolumab and ipilimumab as neoadjuvant therapy for potentially resectable HCC Aspirin and recurrence of PI3K-mutated CRC
October 27, 2025 at 3:42 PM
natrevgastrohep.nature.com
NOVEMBER ISSUE | RESEARCH HIGHLIGHT "Maternal gut microbiome in early pregnancy: predictor of preterm birth?"

www.nature.com/articles/s41...

#Gastrosky #Microsky
Research Highlights: NeuroGASTRO 2025 Maternal gut microbiome in early pregnancy: predictor of preterm birth? Nivolumab and ipilimumab as neoadjuvant therapy for potentially resectable HCC Aspirin and recurrence of PI3K-mutated CRC
October 27, 2025 at 3:42 PM
natrevgastrohep.nature.com
NOVEMBER ISSUE | RESEARCH HIGHLIGHT "NeuroGASTRO 2025"

www.nature.com/articles/s41...

#Gastrosky
Research Highlights: NeuroGASTRO 2025 Maternal gut microbiome in early pregnancy: predictor of preterm birth? Nivolumab and ipilimumab as neoadjuvant therapy for potentially resectable HCC Aspirin and recurrence of PI3K-mutated CRC
October 27, 2025 at 3:42 PM
updates.chemo.org.uk
Nivolumab with ipilimumab- Nivolumab plus ipilimumab for previously untreated patients with microsatellite instability high (MSI-H) or mismatch repair def...

https://updates.chemo.org.uk/CDF_Forms/NIV24.html

🚨 Treatment criteria (#2, 9 and 11) updated
October 24, 2025 at 6:03 PM
swog.org
Latest results from @swog.org DART rare cancers trial, out in J for ImmunoTherapy of Cancer:
Multicenter phase II trial of ipilimumab & nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of DART SWOG S1609 (Cohort 38) jitc.bmj.com/content/13/1...
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors ...
Background Malignant perivascular epithelioid cell tumors (PEComas) are ultra-rare, aggressive mesenchymal neoplasms associated with poor outcomes. Standard-of-care systemic therapy includes mammalian...
jitc.bmj.com
October 22, 2025 at 12:58 PM
onclive.bsky.social
NADINA Trial Favors Neoadjuvant Nivolumab/Ipilimumab in Resectable Stage III Melanoma @myesmo.bsky.social #ESMO25 #ESMO2025 #melsm #oncology
www.onclive.com/view/nadina-...
NADINA Trial Favors Neoadjuvant Nivolumab/Ipilimumab in Resectable Stage III Melanoma | OncLive
Neoadjuvant nivolumab plus ipilimumab proved superior to adjuvant nivolumab alone with longer follow-up data from the NADINA trial in stage III melanoma.
www.onclive.com
October 20, 2025 at 8:32 PM
onclive.bsky.social
CheckMate 8HW Data Further Support Nivolumab/Ipilimumab as a SOC Option in First-line MSI-H/dMMR mCRC @myesmo.bsky.social #ESMO25 #GIoncology #oncology

www.onclive.com/view/checkma...
CheckMate 8HW Data Further Support Nivolumab/Ipilimumab as a SOC Option in First-line MSI-H/dMMR mCRC | OncLive
Nivolumab plus ipilimumab improved PFS and response rates vs nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns.
www.onclive.com
October 20, 2025 at 8:10 PM